Navigation Links
Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in ITP
Date:11/21/2007

e available on Rigel's website, in webcast and podcast formats, approximately 2 hours after the call.

Further information on ITP and R788 in ITP is available at Rigel's website: http://www.rigel.com/rigel/ITP.

About Rigel (http://www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our goal is to file one new investigational new drug (IND) application in a significant indication each year. Rigel has achieved this goal every year since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to the potential efficacy of Rigel's product candidates. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "plans," "intends," "indicates," "promising," "expects," "anticipates" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates, as well as other risks detailed from time to time in Rigel's SEC reports, including its Fo
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Rigel Announces Third Quarter 2007 Financial Results
2. Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study
3. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
4. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
5. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
6. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
7. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
8. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
9. AtriCure to Present at Roth Capital Partners 2007 New York Conference
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. MDS to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 2014 Crosley Law Firm is proud to ... have been named to the list of Super Lawyers in ... of personal injury law. , Before receiving the designation ... selection process. First, they must come highly recommended by a ... noteworthy achievement during the past year by obtaining certain honors, ...
(Date:9/15/2014)... Imaging can be a cost-effective way ... benefit from aggressive intervention, according to a new modeling ... The study looked at people with asymptomatic carotid artery ... blood to the head due to atherosclerosis, or plaque ... up to 20 percent of ischemic strokes, which result ...
(Date:9/15/2014)... Authors Christine Snow and Donna Albury highlight ... four alcoholics. Born out of love and pain and the ... In The Life... ” (published by Xlibris) reveals the struggles ... from the same fate. , Night life is popular ... in this. This book chronicles a typical night in the ...
(Date:9/15/2014)... researchers at the University of Copenhagen have gained ... Parkinson,s disease. The findings have recently been published ... , The defining symptoms of Parkinson,s disease ... is currently no cure for the condition, so ... the potential to shed some light on this ...
(Date:9/15/2014)... 2014 DISCcert, a San Diego based ... DISC Certification Workshop for Oct 16th and 17th. ... to take part in the intensive and highly regarded ... activities that can be immediately implemented into their business ... to educate employees and staff in DISC skills. Learning ...
Breaking Medicine News(10 mins):Health News:Thomas A. Crosley and R. Andrew Rodriguez Named 2014 Super Lawyers 2Health News:RSNA: Imaging Identifies Asymptomatic People at Risk for Stroke 2Health News:RSNA: Imaging Identifies Asymptomatic People at Risk for Stroke 3Health News:Authors show perils of alcohol abuse in new graphic novel 2Health News:Authors show perils of alcohol abuse in new graphic novel 3Health News:Researchers debunk myth about Parkinson's disease 2Health News:DISCcert Announces Two-day DISC Certification Workshop Oct 16 and 17 2Health News:DISCcert Announces Two-day DISC Certification Workshop Oct 16 and 17 3
... are more likely to have their work cited than ... a new study released this week by Rice University,s ... scientists are also more likely to receive greater recognition ... "International Stem Cell Collaboration: How Disparate Policies Between the ...
... Institute of Technology have found support for the theory that ... it stores readily available items. Memory researchers have long debated ... capacity and function of each layer is. In a ... Cognitive Psychology, researchers found that short-term memory is made ...
... new study of a common etiquetteholding a door for someonesuggests ... motivation: to reduce the work for those involved. The research, ... State University, is the first to combine two fields of ... to be published in a forthcoming issue of Psychological ...
... The Nobel prize-winning physicist Richard Feynman once wrote in his ... "When I see equations, I see letters in colors - ... hell it must look like to the students." This neurological ... of "seeing" the letters in colour was a specific form ...
... significantly impacts quality of life for patients after ... Hospital. "Transplant recipients with alcoholic cirrhosis experienced ... reported greater pain and physical limitations than non-alcoholics ... Ford Behavioral Health Services, lead author of the ...
... MESA, Ariz. March 8, 2011 Predictive Biomarker ... produced by Unibioscreen, kills cancer cells. Previous studies ... MCL1 can cause cancer cells to grow out of ... non-profit, Phoenix-based Translational Genomics Research Institute (TGen), co-discovered that ...
Cached Medicine News:Health News:Report: International collaboration between researchers results in greater recognition 2Health News:New study proves the brain has 3 layers of working memory 2Health News:More reasons to be nice: It's less work for everyone 2Health News:Reading in 2 colours at the same time 2Health News:Alcohol abuse history influences quality of life following liver transplant 2Health News:PBS-Bio uncovers how Unibioscreen drug kills cancer 2
(Date:9/15/2014)... , Sept. 16, 2014  Bayer HealthCare and ... Finland , have begun to ... ODM-201, an investigational oral androgen receptor inhibitor in ... in men with castration-resistant prostate cancer who have ... detectable metastases. The trial is designed to determine ...
(Date:9/15/2014)... Sept. 15, 2014 /PRNewswire/ -  Pivotal Therapeutics Inc. ... pharmaceutical company with a focus on Omega-3 therapies ... that the Board of Directors approved the granting ... advisor at the close of business on Friday, September ... 1,000,000 common shares of the Company were granted ...
(Date:9/15/2014)... Sept. 15, 2014 /PRNewswire-iReach/ -- On September 8, ... South Carolina, submitted a Citizen Petition to Dr. ... FDA to add another Black Box Warning to ... request asks for a Black Box Warning for ... paranoia, suicidal thoughts or acts, loss of consciousness, ...
Breaking Medicine Technology:Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 3Pivotal Therapeutics Grants Incentive Stock Options 2Quinolone Vigilance Foundation Supports Citizen Petition Requesting Another Black Box Warning for Levaquin, Cipro, Avelox 2Quinolone Vigilance Foundation Supports Citizen Petition Requesting Another Black Box Warning for Levaquin, Cipro, Avelox 3
... , , FARMINGDALE, N.Y., Jan. 8 Misonix, Inc. ... medical device technology, which in Europe is used for the ... has entered into a new, three year distribution agreement with ... Saudi Arabia, for the distribution of the SonaStar(TM) Ultrasonic Surgical ...
... N.Y., Jan. 8 VirtualScopics, Inc. (Nasdaq: VSCP ... trials, announced today that Ms. Molly Henderson, the company,s ... corporate overview at the upcoming OneMedPlace Finance Forum at ... annually, the OneMedPlace Finance Forum was created to connect ...
Cached Medicine Technology:Misonix Announces New Distribution Agreement for Kingdom of Saudi Arabia 2Misonix Announces New Distribution Agreement for Kingdom of Saudi Arabia 3VirtualScopics to Present at the Upcoming OneMedPlace Investment Conference 2VirtualScopics to Present at the Upcoming OneMedPlace Investment Conference 3
... The FoamWrap ACTION Elbow Wrap replaces messy ... players, golfers, and others experiencing epicondylitis. Preferred ... application and non-bulky fit. Two overlay straps ... Breathable, non-slip foam lining holds the Elbow ...
... Brace is designed to handle post-op elbow ... The Bledsoe Extender Arm Brace should be ... of the elbow is desired. In most ... be formed, fitted and adjusted in 5 ...
... lightweight brace allows it to fit easily into ... joint following severe sprains, tendonitis or after cast ... with the ankle and provide optimum medial-lateral support. ... rotational strains on the ankle, and they provide ...
... stretch ankle support helps reduce swelling and minimize ... It is easy to apply - it slips ... fits easily into shoes. It features bilateral ... provide side-to-side support and stability. This is ...
Medicine Products: